ArticleOncology letters2018
Mesenchymal stem cells expressing interleukin-18 inhibit breast cancer in a mouse model.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 41 citations in OpenAlex.
- Preclinical and Clinical Translation of Immunomodulatory Role of Mesenchymal Stem Cells in Cancer Therapy Era.Tissue engineering and regenerative medicine · 2026Review
- Targeting kinases that regulate programmed cell death: a new therapeutic strategy for breast cancer.Journal of translational medicine · 2025Review
- Mesenchymal Stem Cells in Cancer Therapy.Advances in experimental medicine and biology · 2025Review
- Unlocking the Potential of Induced Pluripotent Stem Cells in Revolutionizing Cancer Therapy.Current stem cell research & therapy · 2025Review
- Revolutionizing Cancer Treatment: Harnessing the Power of Mesenchymal Stem Cells for Precise Targeted Therapy in the Tumor Microenvironment.Current topics in medicinal chemistry · 2025Review
- Review
- A potential immunotherapy target for breast cancer: parenchymal and immune-stromal expression of the NLRP3 inflammasome pathway.BMC cancer · 2023Article
- Interleukin gene delivery for cancer gene therapy:Iranian journal of basic medical sciences · 2023Review
- Engineered adult stem cells: a promising tool for anti-cancer therapy.BMB reports · 2023Review
- Stem Cells for Cancer Therapy: Translating the Uncertainties and Possibilities of Stem Cell Properties into Opportunities for Effective Cancer Therapy.International journal of molecular sciences · 2023Review
- Application of mesenchymal stem cells in tumor therapy.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2022Article
- A combined antitumor strategy of separately transduced mesenchymal stem cells with soluble TRAIL and IFNβ produces a synergistic activity in the reduction of lymphoma and mice survival enlargement.Molecular medicine reports · 2022Article
- MSCs as Tumor-Specific Vectors for the Delivery of Anticancer Agents-A Potential Therapeutic Strategy in Cancer Diseases: Perspectives for Quinazoline Derivatives.International journal of molecular sciences · 2022Review
- Analyzing the influence of IL18 in regulation of YAP1 in breast oncogenesis using cBioportal.Cancer reports (Hoboken, N.J.) · 2022Article
- Glioblastoma Therapy: Rationale for a Mesenchymal Stem Cell-based Vehicle to Carry Recombinant Viruses.Stem cell reviews and reports · 2022Review
- The role of pyroptosis and its crosstalk with immune therapy in breast cancer.Frontiers in immunology · 2022Review
- Molecular Patterns Based on Immunogenomic Signatures Stratify the Prognosis of Colon Cancer.Frontiers in bioengineering and biotechnology · 2022Article
- Molecular Characteristics, Clinical Implication, and Cancer Immunity Interactions of Pyroptosis-Related Genes in Breast Cancer.Frontiers in medicine · 2021Article
- Mesenchymal Stem/Stromal Cells as a Vehicle for Cytokine Delivery: An Emerging Approach for Tumor Immunotherapy.Frontiers in medicine · 2021Review
- Interleukin-18 Is a Prognostic Marker and Plays a Tumor Suppressive Role in Colon Cancer.Disease markers · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Development of an improved breast cancer therapy has been an elusive goal of cancer gene therapy for a long period of time. Human mesenchymal stem cells derived from umbilical cord (hUMSCs) genetically modified with the interleukin (IL)-18 gene (hUMSCs/IL-18) were previously demonstrated to be able to suppress the proliferation, migration and invasion of breast cancer cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.